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ttp://dx.doi.org/10.1016/j.ajpath.2013.06.016Members of the early growth response (Egr) gene family of transcription factors have nonredundant bio-
logical functions. Although Egr-3 is implicated primarily in neuromuscular development and immunity, its
regulation and role in tissue repair and ﬁbrosis has not been studied. We now show that in normal skin
ﬁbroblasts, Egr-3 was potently induced by transforming growth factor-b via canonical Smad3. Moreover,
transient Egr-3 overexpression was sufﬁcient to stimulate ﬁbrotic gene expression, whereas deletion of
Egr-3 resulted in substantially attenuated transforming growth factor-b responses. Genome-wide expres-
sion proﬁling in ﬁbroblasts showed that genes associated with tissue remodeling and wound healing were
prominently up-regulated by Egr-3.Notably,<5%ofﬁbroblast genes regulatedby Egr-1 or Egr-2were found
to be coregulated by Egr-3, revealing substantial functional divergence among these Egr familymembers. In
amousemodel of scleroderma, development of dermalﬁbrosis was accompanied by accumulation of Egr-3e
positivemyoﬁbroblasts in the lesional tissue.Moreover, skin biopsy samples frompatientswith scleroderma
showed elevated Egr-3 levels in the dermis, and Egr-3 mRNA levels correlated with the extent of skin
involvement. These results provide the ﬁrst evidence that Egr-3, a functionally distinct member of the Egr
family with potent effects on inﬂammation and immunity, is up-regulated in scleroderma and is necessary
and sufﬁcient for proﬁbrotic responses, suggesting important and distinct roles in the pathogenesis of
ﬁbrosis. (Am J Pathol 2013, 183: 1197e1208; http://dx.doi.org/10.1016/j.ajpath.2013.06.016)Supported by Department of Defense grant W81-XWH-06-01-0278
(J.V.) and NIH grants R01-AR04239 (J.V.) and R01-NS040748 and K26-
OD010945 (W.G.T.).Scleroderma or systemic sclerosis is an acquired connective
tissue disease of unknown etiology associated with ﬁbrosis
in the skin and internal organs.1e3 Fibrosis is due to persis-
tent activation of ﬁbroblasts and a-smooth muscle actin
(a-SMA)epositive myoﬁbroblasts, resulting in excessive
production and accumulation of collagen and extracellular
matrix (ECM) components in target tissues. There is no
effective therapy to prevent or control the progression of
ﬁbrosis in scleroderma. Transforming growth factor-b (TGF-
b) is a potent inducer of ECM production, myoﬁbroblast
differentiation, and epithelial-mesenchymal transition and is
implicated in physiologic and pathologic tissue repair.4,5
Although the canonical Smad pathway is fundamental in
mediating TGF-b response in ﬁbroblasts, the complex
intracellular signaling networks underlying pathologic
ﬁbrosis remain incompletely understood.stigative Pathology.
.Early growth response (Egr) transcription factors regulate
a wide range of biological processes. The Egr family
comprises Egr-1 (NGFI-A, Krox-24), Egr-2 (Krox-20), Egr-3,
and Egr-4 (NGFI-C), along with their endogenous inhibitors
nerve growth factoreinduced protein A (NGFI-A) binding
proteins NAB1 and NAB2.6,7 The expression of Egr proteins
is induced in a variety of cell types in response to growth
factors, cytokines, hypoxia, and mechanical forces associated
with injury and stress. Egr-1, Egr-2, and Egr-3 share a
conserved zinc-ﬁnger DNA binding domain that recognizes
a 9-bp GC-rich Egr response element found in multiple target
gene promoters.8 Induction of Egr-1 is characteristically rapid
Fang et aland transient,9 whereas induction of Egr-2 and Egr-3 is
delayed and sustained.10,11 Despite their structural similarities
and shared mechanisms of regulation, these three members
of the Egr family are functionally nonredundant in some
systems10,12 and redundant in others.13,14
To date, Egr-3 has been studied primarily in the context of
central nervous system development and in muscle stretch
receptor function, angiogenesis, cancer, and immunity. Egr-3
has an essential role in learning and memory processing.15
Egr-3edeﬁcient mice are ataxic and lack muscle stretch
receptors.16,17 Egr-3 alsohas amajor role in immunity,18 and its
interaction with the forkhead transcription factor FoxO3a is
required for T-cell anergy.19 The previous ﬁnding that ectopic
Egr-3 expression inmyoblasts caused potent stimulation of the
expression of TGF-b1 and collagen genes potentially impli-
catesEgr-3 in connective tissue homeostasis and tissue repair.20
The present studies were undertaken to explore the expression
and regulation of Egr-3 in the context of ﬁbrogenesis and its
function in proﬁbrotic TGF-b signaling. The results show that
in normal ﬁbroblasts, TGF-ß was a potent inducer of Egr-3
expression via the canonical Smad pathway, and Egr-3 eli-
citedmarkedproﬁbrotic responses in these cells. Levels ofEgr-3
were signiﬁcantly up-regulated in scleroderma skin biopsy
samples and in lesional tissue from mice with bleomycin-
induced scleroderma. Taken together, these ﬁndings identify
Egr-3 as a novel TGF-ßeinducible transcription factor with
potent proﬁbrotic effects and altered expression in scleroderma,
suggesting a previously unsuspected role in pathogenesis.
Materials and Methods
Cell Culture and Reagents
Primary cultures of dermal ﬁbroblasts were established by
explantation from skin biopsy samples from healthy adults or
from neonatal foreskin specimens.21 The protocols for skin
biopsies were approved by the Institutional Review Board at
Northwestern University (Chicago, IL). Skin ﬁbroblasts from
4-week-old Egr-3enull mice16 and wild-type littermates,
mouse embryonic ﬁbroblasts from Smad3-null mice,22 and
human ﬁbroblasts were maintained in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% fetal bovine serum
(Lonza, Basel, Switzerland), 50 mg/mL of penicillin, and 50
mg/mL of streptomycin in a humidiﬁed atmosphere of 5%
CO2 at 37C and were studied between passages 2 and 8.
21 At
conﬂuence, fresh serum-free media supplemented with 0.1%
bovine serum albumin were added to the cultures for 24 hours
before the addition of TGF-b2 (PeproTech, Rocky Hill, NJ).
The ß2 isoform of TGF-b was used in these studies because
we had previously shown its robust effects on induction of
ﬁbrotic gene expression in a variety of cell types.10
RNA Isolation and qPCR
At the end of each experiment, cultures were harvested and
RNA was isolated using RNeasy Plus mini kits (Qiagen1198Inc., Valencia, CA) and examined by real-time quantitative
PCR (qPCR).23 One microgram of RNA was used for
cDNA synthesis in 20 mL of reaction volume using cDNA
Synthesis SuperMix (Quanta BioSciences, Gaithersburg,
MD). Eight microliters of cDNA, 2 mL of primers (2 mmol/L
each), and 10 mL of 2 Power SYBR master mix (Applied
Biosystems, Foster City, CA). qPCR was performed in
triplicate using an ABI 7300 thermocycler (Applied Bio-
systems). Data were normalized to 18S RNA, and fold
change was represented as
2DDCt

2½ðCt targetCt 18SÞtreatment  ðCt targetCt 18SÞ nontreatment

:
Western Blot Analysis
At the end of each experiment, ﬁbroblasts were harvested, and
whole cell lysates were examined byWestern blot analysis.10
Antibodies to Egr-3 (Santa Cruz Biotechnology, San Fran-
cisco, CA), type I collagen (SouthernBiotech, Birmingham,
AL), a-SMA (Sigma-Aldrich, St. Louis, MO), and glyceral-
dehyde-3-phosphate dehydrogenase (Zymed Laboratories
Inc., San Francisco, CA) were used for immunoblotting.
Bands were detected using electrochemiluminescence re-
agents (Pierce Biotechnology, Rockford, IL).
ELISAs
Supernatants from conﬂuent cultures of ﬁbroblasts infected
with adenovirus (Ad)eEgr-3 or adenovirus containing green
ﬂuorescent protein (Ad-GFP) as control for 48 hours were
collected and stored at80C. Samples were thawed at room
temperature, and levels of secreted TGF-ß1 were determined
in triplicate using enzyme-linked immunosorbent assay
(ELISA) kits (R&D Systems, Minneapolis, MN) following
the manufacturer’s instructions.
Confocal Immunocytochemical Analysis
Ten thousand ﬁbroblasts per well were seeded onto 8-well
Lab-Tek II chamber glass slides (Nalge Nunc Interna-
tional, Naperville, IL) and were incubated in serum-free
Eagle’s minimal essential medium with 0.1% bovine
serum albumin for 16 hours. Fresh media with 10 ng/mL of
TGF-b2 were then added, and the incubations were
continued for a further 4 hours. At the end of the experi-
ments, cells were ﬁxed, permeabilized, and incubated with
primary antibodies to Egr-3 at 1:200 dilution (Santa Cruz
Biotechnology) or to type I collagen at 1:500 dilution
(SouthernBiotech).24 Cells were then washed with PBS
and incubated with secondary antibodies at 1:500 dilution
(Alexa Fluor 488 and 594; Invitrogen, Carlsbad, CA). Slides
were examined using a Nikon C2 confocal laser scanning
microscope (Nikon Corp, Tokyo, Japan).25 Images were
obtained using Nikon C2 software version 1 (Nikon Corp).
Immunoﬂuorescence signal intensities were quantiﬁed
using ImageJ version 1.46r (NIH, Bethesda, MD).ajp.amjpathol.org - The American Journal of Pathology
Table 1 Clinical Features of Patients with Scleroderma
Study code Age (years)/sex Duration (years)* Skin scorey
N998 27/F NA NA
N999 38/M NA NA
N1004 37/F NA NA
SScMH_06 54/F 3 16
SScMH_15 63/F 5 36
SScMH_17 53/M 1 35
SScMH_37 46/F 0 13
SScReg_1213 30/F 5 4
SScReg_1204 45/F 1 23
*Duration from ﬁrst noneRaynaud disease manifestation.
yModiﬁed Rodnan skin score (range, 0e51).
F, female; M, male; NA, not applicable.
Regulation and Role of Egr-3 in FibrosisPlasmids and Transient Transfection Assays
The Col1A1-luc harbors the truncated human COL1A1
promoter with 50 ends at 759 bp fused to luciferase.26
a-SMAeluc harbors a 1.1-kb promoter fragment from the
mouse a-SMA gene upstream of luc.27 Fibroblasts at 70%
conﬂuence were transfected with the indicated reporter
constructs using the SuperFect transfection kit (Qiagen Inc.).
After 24 hours, ﬁbroblasts were infected with AdeEgr-3 or
control adenovirus.20 Cultures were incubated in serum-free
media containing 0.1% bovine serum albumin for 24 hours.
Cultures were harvested, and whole cell lysates were assayed
for luciferase activities using the dual-luciferase reporter assay
system (Promega Corp., Madison, WI). In each experiment,
Renilla luciferase pRL-TK (PromegaCorp.)was cotransfected
as control for transfection efﬁciency.28 Transient transfectionThe American Journal of Pathology - ajp.amjpathol.orgexperiments were performed in triplicate and were repeated at
least twice with consistent results.
Microarray Procedures and Data Analysis
To examine genome-wide gene expression changes induced
by Egr-3, serum-starved conﬂuent ﬁbroblasts were infected
with AdeEgr-3 or adenovirus containing green ﬂuorescent
protein (Ad-GFP) at 50 multiplicity of infection,20 a
concentration found in preliminary experiments to be optimal
for achieving high levels of cellular Egr-3 expression (data
not shown). After 48 hours of incubation, when close to
100% of infected ﬁbroblasts showed strong GFP expression,
cultures were harvested and total RNA was isolated using
RNeasy Plus mini kits (Qiagen Inc.). The integrity of RNA
was determined using Agilent Bioanalyzer (Agilent Tech-
nologies Inc., Santa Clara, CA). Fluorescently labeled cDNA
was prepared (Ambion, Austin, TX) and was hybridized to
Illumina Human HT-12 version 3 microarray chips contain-
ing 44,000 probes (Illumina Inc., San Diego, CA). Raw
signal intensities for each probe were obtained using Illumina
BeadStudio data analysis software and were imported to the
Bioconductor lumi package for transformation and normal-
ization.29e31 The data were preprocessed using a variance
stabilization transformation method31 followed by quantile
normalization. Data from probes that produced signals near
or below background levels (estimated based on Illumina-
negative control probes) with all samples were discarded.
Genes that showed >1.5-fold up- or down-regulation at 48
hours in Egr-3eexpressing ﬁbroblasts compared with control
ﬁbroblasts were subjected to further analysis.Figure 1 TGF-b stimulated Egr-3 expression.
Conﬂuent foreskin (A, B, D, and E) and healthy
adult skin (C) ﬁbroblasts were incubated in serum-
free media with 10 ng/mL of TGF-b2 (unless
otherwise indicated) for the indicated periods
(A and D), 60 minutes (B and C), and 4 hours (E).
AeC: Total RNA was subjected to qPCR. The results
represent the means  SEM of triplicate determi-
nations from three independent experiments.
**P < 0.01. D: Whole cell lysates were subjected
to Western blot analysis. Representative blot with
the two Egr-3 isoforms indicated. E: Fibroblasts
were immunostained with antibodies to Egr-3
(red) or were stained with DAPI (blue). Repre-
sentative immunoﬂuorescence photomicrographs.
Original magniﬁcation, 60.
1199
Figure 2 Smad-dependent stimulation of Egr-3 expression. A:
Conﬂuent skin ﬁbroblasts were preincubated for 30 minutes with 10 mmol/L
SB431542, followed by 10 ng/mL of TGF-b2 for a further 60 minutes before
RNA isolation and qPCR. The results represent the means SEM of triplicate
determinations. *P < 0.05. B: Fibroblasts from Smad3-null or wild-type
mouse embryos in parallel were incubated with 10 ng/mL of TGF-b2
before RNA harvesting. The results represent the means  SEM of triplicate
determinations from three independent experiments.
Figure 3 Egr-3 regulated Egr-1 and Egr-2 mRNA expression. A: Conﬂuent
ﬁbroblasts were infected with AdeEgr-3 or Ad-GFP. After 48 hours of incuba-
tion, ﬁbroblasts were harvested and RNA was subjected to qPCR analysis. The
results are shown as fold change compared with control Ad-GFP. *P < 0.05,
**P < 0.01 . B: Conﬂuent wild-type (Egr-3þ/þ) and Egr-3/ mouse skin
ﬁbroblasts in parallelwere incubatedwith 10ng/mLof TGF-b2 for the indicated
periods. Total RNA was subjected to qPCR. The results represent the means 
SEM of triplicate determinations from three independent experiments.
Fang et alTo compare Egr-3eregulated genes with those regulated
by Egr-1, Egr-2, or TGF-b, human skin ﬁbroblasts were
infected with AdeEgr-1, AdeEgr-2, or AdeEgr-3 or were
incubated with 10 ng/mL of TGF-b for 48 hours, and RNA
was isolated for microarray analysis.10,24 Bioinformatics
analysis was performed to generate a list of genes showing
a >1.5-fold change in expression in treated versus control
cultures. Gene lists for each treatment were entered into
Microsoft Excel 2010 spreadsheets (Microsoft Corp., Red-
mond, WA) and were analyzed using the vlookup function
to generate lists of genes regulated by Egr-1, Egr-2, and
Egr-3 or both Egr-3 and TGF-b.
Microarray Data Analysis of Scleroderma Skin Biopsy
Samples
Expression of Egr-1, Egr-2, or Egr-3 mRNA was interro-
gated in publicly available scleroderma skin biopsye
derived genome-wide expression microarray data sets (Gene
Expression Omnibus; http://www.ncbi.nlm.nih.gov/geo;
accession number GSE9285).32
Regulation of Egr-3 Expression in Vivo
To examine the regulation of Egr-3 expression in vivo,
scleroderma was induced in 8-week-old female BALB/c
mice by bleomycin injections (The Jackson Laboratory, Bar
Harbor, ME).33 The animal protocols were institutionally1200approved by the Northwestern University Animal Care and
Use Committee. Twenty micrograms of ﬁlter-sterilized
bleomycin per mouse (dissolved in PBS) (Mayne Pharma,
Paramus, NJ) or PBS was administered by s.c. injections for
14 days, mice were sacriﬁced on day 21, and lesional skin
was harvested.34 Each experimental group consisted of
more than three mice. Four-micron sections were processed
for immunohistochemical analysis using primary antibodies
against Egr-3 (Santa Cruz Biotechnology) or a-SMA
(Sigma-Aldrich) at 1:200 dilution. Secondary antibodies
labeled with Alexa Fluor 488 (Invitrogen) at 1:200 or 1:500
dilution were used to detect bound antibodies. Substitution
of the primary antibodies with isotype-matched irrelevant
IgG at the same concentration served as negative controls.
Sections were viewed under a Nikon C2 microscope,25 and
images were acquired using Nikon C2 software. Immuno-
positive cells were counted by a blinded observer (B.Y.) in
ﬁve randomly chosen high-power ﬁelds.
To assess Egr-3 expression in scleroderma, skin biopsy
samples from the affected forearm of patients with early-
stage diffuse cutaneous scleroderma (nZ 6) or healthy adults
(nZ 3) (Table 1) were obtained under protocols approved by
the Institutional Review Boards for Human Studies at
Northwestern University. Clinical features of the participants
are shown in Table 1. Five-micron-thick parafﬁn-embedded
or frozen sections were immunostained with primary anti-
body to Egr-3 (Santa Cruz Biotechnology) followed by
horseradish peroxidaseelabeled secondary antibody (Invi-
trogen). Preincubation of the slides with preimmune serum
served as negative control. Images were acquired using
a Zeiss Axioskop microscope with a CRi Nuance spectralajp.amjpathol.org - The American Journal of Pathology
Figure 4 Egr-3 was sufﬁcient and necessary for
the stimulation of ﬁbrotic gene expression. A and
B: Egr-3 stimulates ﬁbrotic gene expression.
Conﬂuent dermal ﬁbroblasts were infected with
Ad-Egr-3 or Ad-GFP for 48 h. A: Real-time qPCR
(left upper panel). The results of real-time qPCR
are shown as -fold change compared to control,
and represent the means  SEM of triplicate
determinations from three independent experi-
ments. Western immunoblot (right upper panel).
Confocal microscopy after immunostaining with
antibodies to Type I collagen and DAPI. Original
magniﬁcation  60 (lower panels). B: Egr-3
stimulated TGF-ß production, shown using qPCR
and ELISA. C: Fibroblasts transfected with Col1A1-
luc or a-SMAeluc were infected with AdeEgr-3 or
Ad-GFP for 48 hours, and whole cell lysate were
assayed for luciferase activity. D and E: Reduced
TGF-ß responses in ﬁbroblasts lacking Egr-3.
Egr-3enull and wild-type (WT) ﬁbroblasts in
parallel were incubated with 10 ng/mL of TGF-ß2
for 24 hours. Supernatants were analyzed by
Western immunoblot (D) or qPCR (E). The results
are shown as fold change compared with control
and represent the means  SEM of triplicate
determinations from three independent experi-
ments. *P < 0.05, **P < 0.01, ***P < 0.001.
Regulation and Role of Egr-3 in Fibrosiscamera (Carl Zeiss MicroImaging GmbH, Jena, Germany).
The pattern and expression of Egr-3 staining was scored by
a blinded observer (B.Y.) in ﬁve randomly chosen high-
power ﬁelds. Preimmune serum was used in place of
primary antibody as negative controls.
Statistical Analysis
Each experiment was repeated at least three times. Statistical
analysis was performed using the Student’s t-test. Results
are shown as means  SEM; P < 0.05 was considered
statistically signiﬁcant.
Results
TGF-b Stimulates Egr-3 Gene Expression
To shed light on the regulation and function of Egr-3 in the
context of ﬁbrogenesis, neonatal foreskin ﬁbroblasts at
conﬂuencewere incubatedwith TGF-b for up to 48 hours. The
results of qPCR analysis showed that TGF-b stimulated Egr-3
mRNA expression in a time- and dose-dependent manner
(Figure 1AeC). A maximal ﬁvefold increase was seen at 60
minutes, followed by decline to near basal levels by 24 hours.
Adult skin ﬁbroblasts incubated with TGF-b showed an
identical pattern of Egr-3 stimulation (data not shown).
Western blot analysis indicated a time-dependent increase
in Egr-3 protein levels in TGF-betreated ﬁbroblasts, with
a maximal greater than threefold increase at 4 hours, followed
by a gradual decline (Figure 1D). The two Egr-3 isoformsThe American Journal of Pathology - ajp.amjpathol.orgrepresenting different transcription start sites of the Egr-3
gene35 showed comparable responses to TGF-b. Confocal
microscopy conﬁrmed an approximately threefold increase in
Egr-3 localized mostly in the nucleus (Figure 1E).
Intracellular Pathways Mediating Egr-3 Stimulation
To elucidate the intracellular signaling mechanisms under-
lying the stimulation of Egr-3 expression by TGF-b, the
effects of pharmacologic and genetic disruption of Smad
signaling were examined. Pretreatment of ﬁbroblasts with
10 nmol/L SB431542, a selective inhibitor of ALK5-
mediated Smad 2/3 phosphorylation, signiﬁcantly attenu-
ated the stimulation of Egr-3 mRNA (Figure 2A). To further
investigate the role of Smad2/3 in the stimulation of Egr-3,
we examined the effect of TGF-ß in mouse embryonic
ﬁbroblasts lacking Smad3. Incubation of Smad3-null mouse
embryonic ﬁbroblasts with TGF-b resulted in a dramatically
reduced magnitude of Egr-3 stimulation compared with
wild-type ﬁbroblasts (Figure 2B). These results indicate
a dominant role for the canonical Smad2/3 pathway in the
regulation of Egr-3 by TGF-b.
Egr-3 Induces Egr-1 and Egr-2 Gene Expression
Members of the Egr gene family typically exist in func-
tionally linked intracellular networks and coregulate each
other’s expression in many cell types.10,36,37 To examine
whether Egr-3 has a role in regulating the expression of other
Egr genes, the regulation of Egr-1 and Egr-3 was examined1201
Table 2 Top 40 Genes Up-Regulated by Egr-3
Symbol Description
Fold
change
KISS1R KISS1 receptor 11.2
SBSN Suprabasin 7.6
NPW Neuropeptide W 6.9
LFNG LFNG O-fucosylpeptide
3-b-N-acetylglucosaminyltransferase
5.0
HES4 Hairy and enhancer of split 4 (Drosophila) 4.9
HCFC1R1 Host cell factor C1 regulator 1 (XPO1
dependent)
4.7
PENK Proenkephalin 4.3
FGFR3 Fibroblast growth factor receptor 3 4.2
SGK223 Homolog of rat pragma of Rnd2 3.9
CST6 Cystatin E/M 3.7
CUEDC1 CUE domain containing 1 3.7
PRRX2 Paired related homeobox 2 3.6
GPR162 G proteinecoupled receptor 162 3.6
STMN3 Stathmin-like 3 3.5
LOC644063 Heterogeneous nuclear ribonucleoprotein
K pseudogene
3.5
TSPAN17 Tetraspanin 17 3.4
HBA2 Hemoglobin, a2 3.4
KRT86 Keratin 86 3.3
CCNY Cyclin Y 3.2
IRF1 Interferon regulatory factor 1 3.1
RTN4R Reticulon 4 receptor 3.1
SLCO2A1 Solute carrier organic anion transporter
family, member 2A1
3.0
NPTX2 Neuronal pentraxin II 3.0
RSPRY1 Ring finger and SPRY domain containing 1 3.0
SLC7A5 Solute carrier family 7 member 5 3.0
ALPL Alkaline phosphatase, liver/bone/kidney 3.0
SBDSP1 Shwachman-Bodian-Diamond syndrome
pseudogene 1
3.0
NPAS1 Neuronal PAS domain protein 1 3.0
DNLZ DNL-type zinc finger 3.0
C20orf27 Chromosome 20 open reading frame 27 2.9
CCL25 Chemokine (C-C motif) ligand 25 2.9
GRM2 Glutamate receptor, metabotropic 2 2.8
ARC Activity-regulated cytoskeleton-associated
protein
2.8
EIF5 Eukaryotic translation initiation factor 5 2.8
IFI6 Interferon, alpha-inducible protein 6 2.8
TRIB3 Tribbles homolog 3 (Drosophila) 2.7
SUSD2 Sushi domain containing 2 2.7
OSGIN1 Oxidative stress induced growth inhibitor 1 2.7
RAD21 RAD21 homolog (S. pombe) 2.7
NFIC Nuclear factor I/C (CCAAT-binding
transcription factor)
2.7
Fang et alin ﬁbroblasts overexpressing or lacking Egr-3. In ﬁbroblasts
infected with Egr-3 adenovirus, qPCR results showed a more
than sixfold increase in Egr-1 and an approximately twofold
increase in Egr-2 mRNA levels (Figure 3A). Signiﬁcantly,
Egr-3enull skin ﬁbroblasts incubated with TGF-b showed
attenuated stimulation of Egr-1 or Egr-2 gene expression
(Figure 3B). In contrast, neither AdeEgr-1 nor AdeEgr-2
regulated Egr-3 mRNA expression (data not shown).1202Egr-3 Induces Fibrotic Gene Expression and Mediates
TGF-b Responses
To examine the potential effect of Egr-3 on the regulation of
ﬁbrotic responses, human foreskin ﬁbroblasts were infected
with AdeEgr-3 or Ad-GFP virus, and after 48 hours of
incubation, whole cell lysates and total RNA were analyzed
by Western immunoblotting and real-time qPCR. The results
showed that ectopic Egr-3 induced signiﬁcant stimulation of
Col1A1 mRNA and protein expression (Figure 4A). Egr-3
was also shown to induce signiﬁcant stimulation of TGF-b
mRNA and protein expression (Figure 4B). Furthermore,
transient transfection assays demonstrated that Egr-3was able
to transactivate Col1A1 and a-SMA promoters in luciferase
assays (Figure 4C), indicating that the stimulatory response
was mediated at the transcriptional level. To examine the
potential role of Egr-3 as a mediator of the proﬁbrotic
responses elicited by TGF-b, skin ﬁbroblasts from Egr-3e
null mice were studied. Markedly attenuated collagen stim-
ulation by TGF-ß2 in Egr-3enull ﬁbroblasts was conﬁrmed
by Western blot analysis (Figure 4D). Moreover, qPCR
showed that in ﬁbroblasts lacking Egr-3, TGF-ß2 induction of
multiple ﬁbrotic genes (Col1A1, a-SMA, TGFß1, CTGF, and
PAI-1) was signiﬁcantly abrogated (Figure 4E). Together,
these results indicate that Egr-3 is sufﬁcient and necessary for
TGF-beinduced ﬁbrotic responses.
To investigate the genome-wide effects of Egr-3 on ﬁbro-
blast function, microarray expression proﬁling was under-
taken. For this purpose, conﬂuent foreskin ﬁbroblasts were
infected with AdeEgr-3 or Ad-GFP, and after 48 hours of
incubation, RNA was harvested and hybridized to Illumina
microarrays. Analysis of the data showed that Egr-3 over-
expression in ﬁbroblasts resulted in a greater than twofold
change (P < 0.01) in the expression of 638 transcripts of
>48,000 probes. The top 40 Egr-3eregulated genes are
shown in Table 2 and Table 3.
The set of genes showing>1.5-fold change (up or down)was
deﬁned as the “ﬁbroblast Egr-3 signature.” These genes were
subjected to Gene Ontology (GO) and pathway analysis using
DAVID software version 6.7 (http://david.abcc.ncifcrf.gov, last
accessed January 18, 2013)38 to categorize them based on their
known function. The analysis identiﬁed 46 GO functional
categories that were signiﬁcantly enriched with Egr-3e
regulated genes (P < 0.001). Three of the top GO categories
have ascribed function related toECMhomeostasis (Figure 5A).
Included in this category are genes with functions related
to ECM homeostasis, tissue repair, and ﬁbrosis. Real-time
qPCR was performed to conﬁrm changes in the expression of
multiple genes listed in Table 2 (Kiss1R and IRF1) and Table 3
(MMP-1) and selected other genes (Figure 5B and Table 4).
Comparative Analysis of Genes Regulated by Egr-3
Versus Egr-1, Egr-2, and TGF-b
Because Egr-1, Egr-2, and Egr-3 exhibit extensive cross
talk and also regulate each other’s expression to someajp.amjpathol.org - The American Journal of Pathology
Table 3 Top 40 Genes Down-Regulated by Egr-3
Symbol Description Fold change
CFB* Complement factor B 0.1
CXCL6* Chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2) 0.1
IL8* Interleukin 8 0.1
CXCL6* Chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2) 0.1
IL8* Interleukin 8 0.1
SOD2* Superoxide dismutase 2, mitochondrial 0.1
SLC39A8* Solute carrier family 39 (zinc transporter), member 8 0.2
SOD2 Superoxide dismutase 2, mitochondrial 0.2
CXCL1 Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 0.2
C3 Complement component 3 0.2
CCL2 Chemokine (C-C motif) ligand 2 0.2
SLC39A8* Solute carrier family 39 (zinc transporter), member 8 0.2
PTGES Prostaglandin E synthase 0.2
PTX3 Pentraxin 3, long 0.2
LOC644936 Actin, b pseudogene 0.2
NFKBIZ Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta 0.2
IL6 Interleukin 6 (interferon, b 2) 0.3
TAPBP TAP binding protein (tapasin) 0.3
LAMB1 Laminin, b 1 0.3
CXCL12 Chemokine (C-X-C motif) ligand 12 0.3
HSD11B1 Hydroxysteroid (11-b) dehydrogenase 1 0.3
MT2A Metallothionein 2A 0.3
COL6A2* Collagen, type VI, a2 0.3
PABPC1 Poly(A) binding protein, cytoplasmic 1 0.3
MMP3 Matrix metallopeptidase 3 (stromelysin 1, progelatinase) 0.3
MMP1 Matrix metallopeptidase 1 (interstitial collagenase) 0.3
CTSD Cathepsin D 0.3
HLA-B Major histocompatibility complex, class I, B 0.3
CH25H Cholesterol 25-hydroxylase 0.3
COL6A2* Collagen, type VI, a2 0.3
HLA-F Major histocompatibility complex, class I, F 0.3
ABI3BP ABI family, member 3 (NESH) binding protein 0.3
DLGAP4 Discs, large (Drosophila) homolog-associated protein 4 0.3
PKM2 Pyruvate kinase, muscle 0.3
SLC39A14 Solute carrier family 39 (zinc transporter), member 14 0.3
PKM2 Pyruvate kinase, muscle 0.3
COL8A1 Collagen, type VIII, a1 0.3
AKR1B1 Aldo-keto reductase family 1, member B1 (aldose reductase) 0.3
YWHAE Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide 0.3
TNFAIP6 Tumor necrosis factor, a-induced protein 6 0.3
*Duplicates are the result of several probes beingused for each gene. For details see raw data at GEO (http://www.ncbi.nlm.nih.gov/geo; accession number GSE9285).
Regulation and Role of Egr-3 in Fibrosisdegree,10,36,37 we sought to compare the ﬁbroblast Egr-3
signature with the signature of genes regulated by Egr-1
and Egr-2 in these cells using microarray analysis.
Twenty-two genes were found to be regulated by all three
Egr proteins (Figure 6). Among these, 5% of genes regu-
lated by Egr-1 and 4% of genes regulated by Egr-2 were
also regulated by Egr-3. One of the genes prominently
regulated by all three Egr proteins is procollagen-lysine,
2-oxoglutarate 5-dioxygenase 1 (Plod1), an enzyme that
plays a key role in the generation of hydroxylysine alde-
hydeederived collagen cross-links and is implicated in
ﬁbrosis.39 Twenty-four genes were coregulated by Egr-3
and TGF-b, including Egr-2 and a-SMA (Figure 6B).
To examine the potential roles of Egr-1, Egr-2, and Egr-3
in scleroderma, a publicly available expression microarrayThe American Journal of Pathology - ajp.amjpathol.orgdata set of extensively characterized scleroderma skin
biopsy samples was interrogated.32 Analysis of the data set
consisting of 26 scleroderma biopsy samples indicated that
Egr-3 mRNA expression was correlated with Egr-2 mRNA
level in individual biopsy samples (R2Z 0.5205, P < 0.01),
whereas no correlation with Egr-1 mRNA (R2 Z 0.0302,
P > 0.05) was found (Figure 6C).
Egr-3 Expression Is Elevated in a Mouse Model of
Scleroderma
In light of the proﬁbrotic activities associated with Egr-3
and its role in mediating TGF-ß responses in ﬁbroblasts,
we next sought to characterize Egr-3 expression in an
experimentally induced model of ﬁbrosis in the mouse.1203
Figure 5 Egr-3 induced genome-wide changes in ﬁbroblast gene
expression. A: Conﬂuent dermal ﬁbroblasts were infected with AdeEgr-3 or
Ad-GFP for 48 hours, and RNA was hybridized to Illumina chips containing
48,000 probes. Genes showing>1.5-fold change in expression were subjected
toGOanalysis. Shown are the top14GOcategories (P valueswere calculated by
DAVID software version 6.7).B: Expression of selected genes was examined by
qPCR analysis using the same RNA as used for the microarray hybridizations.
The results represent the means  SEM. *P < 0.05, **P < 0.01.
Fang et alSubcutaneous injection of bleomycin induces progressive
scleroderma-like skin and lung ﬁbrosis in BALB/c mice.40
Bleomycin-injected mice showed increased dermal thick-
ness at 21 days that was associated with a substantial
increase in Egr-3 immunostaining (Figure 7A). Examination
of sequential slides showed that 26% of Egr-3epositive
cells in the dermis also showed positive a-SMA immuno-
staining (data not shown). Double immunoﬂuorescence
staining was used to further characterize the colocalization
of Egr-3 and myoﬁbroblasts. The results showed a dramatic
increase in Egr-3 nuclear accumulation and a-SMA immu-
nostaining in the lesional skin in bleomycin-injected mice
(Figure 7B). Moreover, 38% of Egr-3epositive cells were
also positive for a-SMA. Egr-3 expression was also ob-
served in a-SMAenegative cells.
Egr-3 Expression Is Up-Regulated in Scleroderma Skin
Biopsy Samples
To examine the expression of Egr-3 in scleroderma, im-
munohistochemical analysis of skin biopsy samples fromTable 4 qPCR Conﬁrmation of Differentially Expressed Genes in Egr-3e
Gene symbol Fold change
qPCR fold change
(means  SEM) GO cate
IRF1 3.1 2.8  0.3 GO:006
Kiss1R 11.2 4.2  0.4 GO:005
a-SMA 2.0 1.8  0.3 GO:001
CTGF 1.8 2.4  0.3 GO:003
Plod1 1.8 2.2  0.4 GO:003
Egr-2 1.8 2.3  0.2 GO:000
MMP1 0.3 0.3  0.1 GO:003
MMP3 0.3 0.2  0.08 GO:003
1204patients with scleroderma (nZ 6) and healthy adults (nZ 3)
in parallel was performed. The clinical features of the patients
and controls are shown in Table 1. In the epidermis,
comparable Egr-3 staining was seen in scleroderma and
control skin biopsy samples, with the most marked expres-
sion in the basal layer (Figure 8, A and B). In contrast, in the
dermis, strong Egr-3 expression was noted only in sclero-
derma, but not control, biopsy samples (Figure 8, C and D).
The speciﬁcity of the antieEgr-3 antibody was conﬁrmed by
Western immunoblots (Figure 1C). Incubation of skin biopsy
samples with preimmune serum further demonstrated the
speciﬁcity of immunostaining.
To evaluate Egr-3 mRNA expression in scleroderma,
a previously reported extensively characterized genome-
wide expression microarray data set from skin biopsy
samples32 was interrogated. The analysis showed a positive
correlation of Egr-3 mRNA levels with the modiﬁed
Rodnan skin score, a validated index of skin involvement
(R2 Z 0.4213, P < 0.01) (Figure 8E).
Discussion
In this study, we examined the regulation, expression, and
function of the transcription factor Egr-3 in the ﬁbrogenesis
context. The results demonstrate that the expression of Egr-
3 in ﬁbroblasts is directly stimulated by TGF-ß. In contrast
to Egr-2, Egr-3 shows rapid and transient induction similar
to Egr-1. In normal ﬁbroblasts, Egr-3 elicits a broad ﬁbro-
genic response, with potent up-regulation of several genes
for collagens and other ECM genes. The ﬁbroblast Egr-3
response gene signature shows only a modest overlap with
the pattern of gene regulation elicited by either Egr-1 or Egr-
2, highlighting its distinct functional role. In light of its
potent proﬁbrotic effects and its elevated expression in
lesional scleroderma tissue, and in a mouse model of
scleroderma, the present results implicate Egr-3 as a medi-
ator of TGF-ßeregulated ﬁbrosis important in the patho-
genesis of scleroderma.
Multiorgan ﬁbrosis causes signiﬁcant morbidity and
mortality in scleroderma.1e3 Fibrosis is a complex process
involving aberrant ﬁbroblast activation, increased synthesis
and deposition of collagens and ECM molecules, and
differentiation and persistence of contractile myoﬁbroblastsOverexpressing Fibroblasts
gory
0337: type I interferon-mediated signaling pathway
1496: positive regulation of stress fiber assembly
5629: actin cytoskeleton
1012: ECM
0198: extracellular matrix organization
3700: sequence-specific DNA binding transcription factor activity
1012 ECM
1012 ECM
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Figure 6 Correlation of Egr expression and Egr
signature in vitro and in scleroderma biopsy
samples. A and B: Human skin ﬁbroblasts were
infected with AdeEgr-1, AdeEgr-2, or AdeEgr-3
or were incubated with 10 ng/mL of TGF-b for 48
hours. RNA was isolated for microarray analysis.
The Venn diagrams show the overlap of genes
whose expression was up- (A) or down-regulated
(B) >1.5-fold by Egr-3. The boxes list the genes
that overlap. C: mRNA levels were interrogated in
publicly available scleroderma skin biopsyederived
genome-wide expression data sets.32 Fold change
in mRNA levels was normalized with average
expression levels of the samples in the entire
cohort.
Regulation and Role of Egr-3 in Fibrosiswith stiffening of the connective tissue.41 Substantial
evidence implicates TGF-ß as a key trigger that initiates and
sustains ﬁbroblast activation and myoﬁbroblast differentia-
tion in pathologic ﬁbrogenesis.4 In the past decade, a variety
of intracellular signaling networks have been identiﬁed that
mediate proﬁbrotic TGF-ß responses.42 In addition to the
canonical Smad pathway, ERK, FAK, Akt, c-Abl, Egr-1,
and Egr-2 have recently also been shown to function as
important nodes in TGF-ßedependent signaling networks
that are dysregulated and likely to play important roles in
ﬁbrosis.43 The present studies are the ﬁrst to demonstrate
that Egr-3 is a novel mediator of TGF-ßeregulated ﬁbro-
genesis and a potential target for antiﬁbrotic therapy. We
show herein that Egr-3 expression is up-regulated in the skin
of mice with bleomycin-induced scleroderma and that
increased expression is closely associated with myoﬁbro-
blast accumulation in the lesional dermis. Moreover,
elevated Egr-3 expression is observed in skin biopsy
samples from patients with scleroderma, and Egr-3 mRNA
levels show a positive correlation with the Rodnan skin
score.44 The results show that TGF-ß2 induced the expres-
sion of Egr-3, which, in turn, mediated broad changes in
ﬁbroblast gene expression. Of interest, these microarray
studies demonstrated that the core “ﬁbroblast Egr-3 gene
signature” comprising several ECM-related genes overlaps
only modestly with the genes regulated by the closely
related transcription factors Egr-1 and Egr-2. Together,
these observations identify Egr-3 as a functionally distinct
factor with a potentially important role in the pathogenesis
of scleroderma.
Early growth response genes are implicated in multiple
physiologic and pathologic processes.12 In contrast to Egr-1The American Journal of Pathology - ajp.amjpathol.organd Egr-2, which have been studied in ﬁbroblasts, the
function of Egr-3 is poorly understood. Previous studies
demonstrating that Egr-3 directly regulates TGF-ß expres-
sion in neural cells provided the rationale for investigating
the regulation and function of Egr-3 in ﬁbrogenesis.20 Egr-
1, Egr-2, and Egr-3 bind to similar GC-rich DNA sequences
via highly homologous zinc ﬁnger DNA-binding domains
and exhibit functional redundancy in some cells. Previous
studies have implicated Egr-3 in inﬂammation, autoimmu-
nity, angiogenesis, and cancer.12 Although Egr-3enull mice
are viable, 40% die before postnatal day 21.17 These mice
show severe abnormalities in sympathetic nervous
system45,46 and T-cell46 development. Moreover, Egr-3 has
an important role in angiogenesis, and in endothelial cells it
is one of the most highly up-regulated genes in response to
vascular endothelial growth factor.47 In addition, Egr-3 has
potent effects on inﬂammation and immunity and negatively
regulates T-cell function.36,48 In T cells, Egr-3 expression is
induced by engagement of the T-cell receptor in an NFAT-
dependent manner.19,49 Egr-3enull mice are resistant to
anergy induction in vivo and show increased susceptibility to
autoimmune pneumonitis.36,48 Indeed, Egr-3 is indispensible
for preventing the development of lupus-like autoimmunity
in mice.50 At the same time, mice with lupus-like manifes-
tations have diminished expression of Egr-3, and a peptide
that ameliorated the autoimmune phenotype was shown to
enhance Egr-3 expression.51 The inhibitory effect of Egr-3 on
CD4þ and CD8þ T-cell effector function involve a dual
action of inhibiting the induction of activating genes while
simultaneously promoting the expression of inhibitory genes
through Sprouty 1.52 Indeed, in T cells overexpressing Egr-3,
Egr-3 binds directly to the Sprouty 1 promoter. Moreover, by1205
Figure 8 Elevated Egr-3 expression in scleroderma skin. Skin biopsies
from healthy individuals (n Z 3) and patients with scleroderma (n Z 6)
were examined by immunohistochemical analysis using primary antibodies
to Egr-3. A: Representative images of the epidermis. B: Quantiﬁcation of
Egr-3epostive cells in the epidermis. Bars represent means  SD. C:
Representative images of dermis. Arrows indicate Egr-3epositive cells. D:
Quantiﬁcation of Egr-3epositive cells in the dermis. *P < 0.05. E: Levels of
Egr-3 mRNA in scleroderma skin biopsies were interrogated in a publicly
available genome-wide expression microarray data set and were normalized
with average expression levels in the entire cohort and correlated with the
modiﬁed Rodnan skin score (MRSS) for each biopsy sample.32 Results are
the means  SEM from ﬁve randomly chosen high-power ﬁelds (HPFs).
Original magniﬁcation: 100 (A); 400 (C).
Figure 7 Elevated Egr-3 expression in ﬁbrotic dermis in the mouse.
Mice received daily s.c. injections of bleomycin or PBS, and lesional skin
was harvested on day 21. A: H&E (left column) or immunohistochemical
analysis using Egr-3 antibody. Arrows indicate the extent of the dermis.
Boxed areas in the middle column correspond to higher-magniﬁcation
images in the right column. B: Double-labeled immunoﬂuorescence.
Sections were immunostained with antibodies to Egr-3 (red), a-SMA
(green), or DAPI (blue), and images were acquired using Nikon confocal
microscopy. Arrows indicate a-SMAe and Egr-3epositive dermal cells.
Dotted lines delineate the epidermis. Original magniﬁcation: 100 (main
images, A); 400 (boxed areas, A); 600 (B).
Fang et alvirtue of its ability to modulate angiogenesis, inﬂammation,
immunity, and apoptosis, Egr-3 is strongly linked with
tumorigenesis, and its expression is highly up-regulated in,
and is predictive of the outcome of, prostate cancer.53
The expression of Egr family proteins is regulated by
a variety of hormones, cytokines, and growth factors. We
show herein, for the ﬁrst time, that TGF-b is a potent stimulus
for Egr-3 expression. Other mediators of ﬁbrosis, including
the canonical Wnt ligand Wnt3a, also stimulates Egr-3
expression (manuscript in preparation). However, TGF-ß
regulation of Egr-3, unlike that of Egr-1 and Egr-2, produces
a relatively sustained response that is independent of
canonical Smad signaling. Moreover, our gain-of-function
and loss-of-function studies demonstrated that Egr-3 is
capable of modulating the expression of Egr-1 and Egr-2. To
identify target genes that are regulated by Egr-3, we per-
formed microarray analysis in normal ﬁbroblasts over-
expressing Egr-3. These studies led to the identiﬁcation of
a “ﬁbroblast Egr-3eresponsive gene signature” that was1206signiﬁcantly enriched with genes implicated in ECM
homeostasis. One of the genes most highly up-regulated by
Egr-3 was KISS1R, also called G proteinecoupled receptor
54 (GPCR54), a receptor for the Kiss ligand.54 Kiss1R is
known to be expressed in the brain (cerebellum, cerebral
cortex, and brainstem)55 and has been implicated in playing
roles in metastasis56 and fertility.57 Interaction of Kiss1R
with EGFR results in stimulation of matrix metalloprotease 9
activity and enhanced breast cancer cell invasiveness.58 The
present results demonstrate that in ﬁbroblasts, ectopic Egr-3
induces Kiss1R, suggesting a potential role for the Kiss
ligand-receptor axis in ﬁbrogenesis. Consistent with other
reports, we found that the overlap between genes regulated
by Egr-3 and those regulated by Egr-1 and Egr-2 is modest,ajp.amjpathol.org - The American Journal of Pathology
Regulation and Role of Egr-3 in Fibrosisindicating a substantial degree of functional heterogeneity
among these structurally similar transcription factors.
The present studies are the ﬁrst to implicate Egr-3 in
ﬁbrosis and scleroderma. The results indicate increased
expression of Egr-3 in experimental mouse scleroderma,
with double-labeling studies demonstrating Egr-3 expres-
sion in the ﬁbrotic skin primarily in interstitial myoﬁbro-
blasts, contractile stromal cells with a crucial role in
pathologic tissue remodeling.59 The present studies show
that the number of Egr-3epositive myoﬁbroblasts was
markedly increased in the ﬁbrotic skin of bleomycin-treated
mice. The ﬁndings are consistent with the observation that
Egr-3 stimulates the transcription of a-SMA, a key deter-
minant of the myoﬁbroblast phenotype.59 We also found
that Egr-3 expression was markedly up-regulated in skin
biopsy samples from patients with scleroderma. Because of
the relatively small size of the study cohort, it was not
possible in this study to establish a robust correlation
between Egr-3 expression and disease activity, progression,
or outcome (data not shown); future studies to examine
these important questions could be highly informative.
In summary, the present results demonstrate that Egr-3 is
a TGF-ßeinducible transcription factor that in ﬁbroblasts
induces ﬁbrotic gene expression in response to TGF-b. We
demonstrate aberrant Egr-3 expression in a mouse model of
scleroderma and in skin biopsies from scleroderma patients.
Together, these ﬁndings suggest that Egr-3 is a novel compo-
nent of the intracellular signaling network that, along with
Smads, Egr-2, and Eg-1, plays essential roles in orchestrating
long-term ﬁbrogenic responses elicited by TGF-ß, and other
proﬁbrotic stimuli. Egr-3 appears to have an important
and previously unsuspected role in the pathogenesis of
scleroderma.
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